FCGR2B and breast neoplasm: Supporting a role for antibody effector function in the efficacy of trastuzumab, mice lacking the inhibitory CD32B (FcγRIIB) demonstrated enhanced trastuzumab-dependent cell-mediated cytotoxicity whereas mice deficient in activating FcγR were unable to inhibit tumour growth in mouse xenograft breast tumour model23.